Related to BioFactura Scores Nearly $2M for Ebola Therapy and VRP Vaccine Production

• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Scancell Gains Rights to mAb from CRT for Immunotherapy Development
  
• Nabi Scores Another $8M from GSK under MRSA Vaccine Deal
  
• Emergent BioSolutions and TLV Set Up Influenza-Focused JV
  
• Advaxis and Vibalogics to Co-Develop Stable Storage Formulation for Live Vaccines
  
• Selecta Awarded $3M by NIDA to Progress Synthetic Nicotine Vaccine into Clinic
  
• Researchers Discover How Some Pathogens Evade the Immune System
  
• Emergent Wins $28.7M NIAID Contract for Development of Third-Gen Anthrax Vaccine
  
• FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test
  
• Novartis and Collaborators Discover Candidate for Drug-Resistant Malaria
  
• Pevion’s Investors Commit Further $9.7M to Progress Virosome-Based Vaccines
  
• DSM Wins Manufacturing Contract for PolyTherics’ PEGylated IFN Alpha-2a Candidate
  
• FDA to Assess Glythera Technology for Carbohydrate-Based Conjugate Vaccines
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• Edimer Signs On CMC Biologics to Produce Recombinant Protein for Clinical Trials
  
• Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III
  
• Sanofi Pasteur to Purchase VaxDesign for $55M
  
• ThromboGenics Taps MSD for Long-Term Commercial Supply of Microplasmin
  
• SAFC Adds 50,000 Square Feet to Jerusalem Site to Bump Up Fermentation Capabilities
  
• GenVec Receives Second-Year Funding from SAIC for HIV and Flu Vaccine Development